

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/220098 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) *A61P 35/04* (2006.01)
A61K 31/403 (2006.01) *C07D 471/10* (2006.01)
A61K 31/427 (2006.01) *C07D 519/00* (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2023/021604

(22) International Filing Date:

09 May 2023 (09.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/339,635 09 May 2022 (09.05.2022) US

(71) Applicant: SYNDAX PHARMACEUTICALS, INC.

[US/US]; 35 Gatehouse Drive, Building D, Floor 3,
Waltham, MA 02451 (US).

(72) Inventors: MORRISON, Briggs, W.; 103 Madison St.

Newton, PA 18940 (US). MCGEEHAN, Gerard, M.; 3741
Rosemont Pass, Newtown Square, PA 19073 (US).

(74) Agent: ERLACHER, Heidi, A. et al.; 1299 Pennsylvania Avenue, NW, Suite 700, Washington, DC 20004-2400 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCER



(Compound A).




FIG. 1

(57) Abstract: The present disclosure is directed to methods of treating colorectal cancer in a subject in need thereof with a menin-MLL inhibitor, including Compound A. Methods for dosing Compound A for various indications are also provided by the present disclosure.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*